Skip to Main ContentSkip to FooterSkip to Search
  1. Home
  2.  » 
  3. Expert Content
  4.  » 
  5. Biologics Development
  6.  » The Post-COVID Supply Chain

The Post-COVID Supply Chain

Summary: While drug supply chains generally held up during the pandemic, it was no easy feat. COVID-19 taught the industry just how vulnerable the far-flung supply chain could become, and it spawned new efforts to regionalize manufacturing and double down on automation. During this panel discussion, executives from Alnylam, Sandoz, Bayer, Amgen and Catalent share how their companies adapted to the challenges and what lessons they will take forward to ensure secure supply chains for the long haul.

Click here to view the webinar